Charmacy Pharmaceutical Co., Ltd. (HKG:2289)

Charmacy Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	509.97	563.15	634.2	492.67	630.17	590.32
Short-Term Investments	11.21	10.7	10.56	11.13	11.59	11.7
Cash & Short-Term Investments	521.18	573.86	644.76	503.81	641.76	602.02
Cash Growth	24.86%	-11.00%	27.98%	-21.50%	6.60%	16.33%
Accounts Receivable	1,243	1,226	965.35	865.26	731.26	763.99
Other Receivables	47.55	43.12	41.49	116.91	42.8	44.54
Receivables	1,291	1,270	1,007	982.17	774.06	808.54
Inventory	721.87	655.91	775.84	586.85	509.16	585.01
Prepaid Expenses	-	1.84	-	-	-	-
Other Current Assets	545.21	528.84	384.56	389.53	313.25	255.74
Total Current Assets	3,079	3,030	2,812	2,462	2,238	2,251
Property, Plant & Equipment	307.67	317.6	328.55	294.08	348.44	372.5
Goodwill	6	6	6.02	6.02	6.02	6.02
Other Intangible Assets	70.45	72.49	76.72	80.86	143.03	152.19
Long-Term Deferred Tax Assets	8.27	7.64	7.38	6.8	8.16	9.29
Long-Term Deferred Charges	20.69	22.91	16.98	16.34	19.21	8.09
Total Assets	3,492	3,457	3,248	2,866	2,763	2,799
Accounts Payable	1,073	826.51	936.49	876.78	809.77	938.61
Accrued Expenses	56.03	61.29	58.35	86.48	47.84	55
Short-Term Debt	1,121	1,350	1,338	1,166	1,193	1,086
Current Portion of Long-Term Debt	9.24	1.22	-	-	31.78	31.84
Current Portion of Leases	1.24	8.78	6.59	4.15	2.97	2.69
Current Income Taxes Payable	9.57	11.72	12.85	27.05	6.41	14.28
Current Unearned Revenue	2.3	2.1	19.49	13.53	46.66	5.01
Other Current Liabilities	553.91	526.5	247.55	81.98	20.44	28.4
Total Current Liabilities	2,826	2,789	2,619	2,256	2,159	2,162
Long-Term Debt	43.2	13.8	-	-	86.87	118.46
Long-Term Leases	30.66	35.17	30.39	15.75	12.49	15.33
Long-Term Unearned Revenue	-	-	-	-	0.3	0.76
Long-Term Deferred Tax Liabilities	0.18	0.38	0.6	0.06	0.4	0.31
Total Liabilities	2,900	2,838	2,650	2,271	2,259	2,297
Common Stock	108	108	108	108	108	108
Additional Paid-In Capital	278	278	278	278	278	278
Retained Earnings	204.84	231.7	210.82	208.07	117.11	115.56
Comprehensive Income & Other	0.99	0.99	0.99	0.99	0.99	0.99
Total Common Equity	591.83	618.69	597.81	595.06	504.1	502.55
Shareholders' Equity	591.83	618.69	597.81	595.06	504.1	502.55
Total Liabilities & Equity	3,492	3,457	3,248	2,866	2,763	2,799
Total Debt	1,205	1,409	1,375	1,186	1,327	1,254
Net Cash (Debt)	-684.28	-835.6	-729.76	-681.72	-685.4	-652.46
Net Cash Per Share	-6.34	-7.74	-6.76	-6.31	-6.35	-6.04
Filing Date Shares Outstanding	108	108	108	108	108	108
Total Common Shares Outstanding	108	108	108	108	108	108
Working Capital	252.79	241.39	193.14	206.77	79.3	89.32
Book Value Per Share	5.48	5.73	5.54	5.51	4.67	4.65
Tangible Book Value	515.38	540.2	515.06	508.18	355.04	344.33
Tangible Book Value Per Share	4.77	5.00	4.77	4.71	3.29	3.19
Buildings	298.92	298.21	298.21	269.2	329.71	329.85
Machinery	82.32	80.86	81.06	76.69	101.72	100.26
Construction In Progress	-	-	-	-	-	1.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.